Studies have shown that Black patients are less likely to receive newer diabetes medications, including SGLT-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), than White patients [23,24]. The gene discussed is GLP1R; the disease is diabetes mellitus.